{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:07:45Z","timestamp":1770739665745,"version":"3.49.0"},"reference-count":10,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"DOI":"10.3201\/eid1306.070154","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T17:30:35Z","timestamp":1336498235000},"page":"953-955","source":"Crossref","is-referenced-by-count":25,"title":["Invasive Cryptococcosis and Adalimumab Treatment"],"prefix":"10.3201","volume":"13","author":[{"given":"Juan P.","family":"Horcajada","sequence":"first","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor M.","family":"Mart\u00ednez-Taboada","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinitario","family":"Pina","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Belaustegui","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Eliecer","family":"Cano","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Garc\u00eda-Palomo","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Carmen","family":"Fari\u00f1as","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1822","published-online":{"date-parts":[[2007,6]]},"reference":[{"key":"key-10.3201\/eid1306.070154-201205080400-R1","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"key-10.3201\/eid1306.070154-201205080400-R2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1699-258X(07)73593-3","article-title":"Spanish registry of adverse events of biologic therapies in rheumatic diseases. (BIOBADASER). Report of the situation on January 2006","volume":"3","author":"Descalzo","year":"2007","journal-title":"Reumatologia Clinica."},{"key":"key-10.3201\/eid1306.070154-201205080400-R3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key-10.3201\/eid1306.070154-201205080400-R4","unstructured":"US Food and Drug Administration. Arthritis Drugs Advisory Committee: safety update on TNF-\u03b1 antagonists: infliximab and etanercept. [cited 2007 Mar 13]. Available from http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3779b2.htm"},{"key":"key-10.3201\/eid1306.070154-201205080400-R5","first-page":"1561","article-title":"Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab.","volume":"29","author":"True","year":"2002","journal-title":"J Rheumatol"},{"key":"key-10.3201\/eid1306.070154-201205080400-R6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1378\/chest.124.6.2395","article-title":"Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy.","volume":"124","author":"Hage","year":"2003","journal-title":"Chest"},{"key":"key-10.3201\/eid1306.070154-201205080400-R7","first-page":"606","article-title":"Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel.","volume":"49","author":"Shrestha","year":"2004","journal-title":"Respir Care"},{"key":"key-10.3201\/eid1306.070154-201205080400-R8","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1128\/IAI.70.6.2959-2964.2002","article-title":"Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell\u2013mediated immunity to pulmonary Cryptococcus neoformans infection.","volume":"70","author":"Herring","year":"2002","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid1306.070154-201205080400-R9","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.4049\/jimmunol.157.10.4529","article-title":"Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.","volume":"157","author":"Huffnagle","year":"1996","journal-title":"J Immunol"},{"key":"key-10.3201\/eid1306.070154-201205080400-R10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3201\/eid0401.980109","article-title":"What makes Cryptococcus neoformans a pathogen?","volume":"4","author":"Buchanan","year":"1998","journal-title":"Emerg Infect Dis"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/13\/6\/07-0154_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T14:22:01Z","timestamp":1732630921000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/13\/6\/07-0154_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6]]}},"URL":"https:\/\/doi.org\/10.3201\/eid1306.070154","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}